Clinical Trial

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 27, 2024 (before its estimated June 6, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn ifDisitamab Vedotin in combination with tislelizumab and bevacizumab can treat in locally advanced or metastatic non-small cell lung cancer patients with HER2 mutation/amplification/expression. The main questions it aims to answer are: 1. objective response rate; 2. Progression-Free Survival; 3. Overall Survival; 4. Disease Control Rate; 5. Duration of Response.
Trial Details
NCT Number NCT06749860
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions Lung Cancer
Enrollment 58 participants
Start Date 2024-02-02
Primary Completion 2026-06-06 (estimated)
Study Completion 2027-06-06 (estimated)
Updated on ClinicalTrials.gov 2024-12-27